This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ifetroban
DrugBank Accession Number
DB12321
Background

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 440.54
Monoisotopic: 440.231122138
Chemical Formula
C25H32N2O5
Synonyms
  • Ifetroban
External IDs
  • BMS-180291

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Ifetroban is combined with Abciximab.
AbrocitinibThe risk or severity of bleeding and thrombocytopenia can be increased when Ifetroban is combined with Abrocitinib.
AceclofenacThe risk or severity of bleeding can be increased when Aceclofenac is combined with Ifetroban.
AcemetacinThe risk or severity of bleeding can be increased when Acemetacin is combined with Ifetroban.
AcenocoumarolThe risk or severity of bleeding can be increased when Ifetroban is combined with Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Ifetroban.
AlclofenacThe risk or severity of bleeding can be increased when Alclofenac is combined with Ifetroban.
AldesleukinThe risk or severity of bleeding can be increased when Ifetroban is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Ifetroban is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Ifetroban is combined with Alteplase.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Ifetroban Sodium48IJA0E92C156715-37-6WOHSQDNIXPEQAE-QBKVZTCDSA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
2-heteroaryl carboxamides / 2,4-disubstituted oxazoles / Benzene and substituted derivatives / Oxolanes / Heteroaromatic compounds / Secondary carboxylic acid amides / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids
show 5 more
Substituents
2,4-disubstituted 1,3-oxazole / 2-heteroaryl carboxamide / 3-phenylpropanoic-acid / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
E833KT807K
CAS number
143443-90-7
InChI Key
BBPRUNPUJIUXSE-DXKRWKNPSA-N
InChI
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
IUPAC Name
3-(2-{[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}phenyl)propanoic acid
SMILES
CCCCCNC(=O)C1=COC(=N1)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1CC1=CC=CC=C1CCC(O)=O

References

General References
Not Available
PubChem Compound
3037233
PubChem Substance
347828584
ChemSpider
16736637
BindingDB
50212318
ChEMBL
CHEMBL3301673
ZINC
ZINC000003793091
Wikipedia
Ifetroban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAspirin Exacerbated Respiratory Disease (AERD)1
2CompletedTreatmentCirrhosis of the Liver / Portal Hypertension1
2CompletedTreatmentHepato-Renal Syndrome1
2RecruitingTreatmentAspirin Exacerbated Asthma1
2RecruitingTreatmentAspirin Exacerbated Asthma / Aspirin Exacerbated Respiratory Disease (AERD) / Aspirin-sensitive Asthma With Nasal Polyps / Polyps, Nasal1
2RecruitingTreatmentAutoimmune Disorder / Connective Tissue Diseases / Pathologic Processes / Scleroderma, Limited / Scleroderma, Systemic / Skin Diseases / Systemic Sclerosis, Diffuse / Systemic; Sclerosis, Progressive1
2RecruitingTreatmentCardiovascular Disease (CVD) / Vasodilation1
2RecruitingTreatmentDilated Cardiomyopathy (DCM) / Duchenne Muscular Dystrophy Cardiomyopathy1
2RecruitingTreatmentSolid Malignant Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0146 mg/mLALOGPS
logP4ALOGPS
logP3.95ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)4.65ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.66 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity119.24 m3·mol-1ChemAxon
Polarizability48.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:57 / Updated at February 21, 2021 18:53